Navigation Links
Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook

PHILADELPHIA and LONDON, July 22 /PRNewswire/ -- The 2009 edition of the trusted and often cited compendium of pharmaceutical research and development statistics, the CMR International Pharmaceutical R&D Factbook, is now available. This year's Factbook offers extended content including patent information and emerging trends in worldwide pharmaceutical R&D.

"The R&D Factbook provides the data that R&D companies need to make informed decisions," said Dr. Jane Sharples, General Manager of CMR International. "With this publication, R&D companies can gain insights into industry dynamics and trends, determine how they perform against the market as a whole and gauge their productivity in relation to their peers and competitors. Companies can also see the consequences of adopting different R&D strategies. In short, they have accurate, independent and validated information on which to base business decisions."

Highlights of the 2009 edition include:

  • The number of new molecular entities (NME) launched onto the global market failed to improve on 2008's 20-year low. Actual development times for new molecular entities are slowly increasing to 14 years, though major pharmaceutical companies (those that spent more than $2 billion on R&D in 2008) take on average slightly more than 11 years.
  • Anti-cancer therapy is the most common area for new patent filing on emerging targets.
  • India leads the way in the recent trend towards new molecular entity research by generic specialty companies.

The Centre for Medicines Research International Ltd (CMR International), a Thomson Reuters business, yearly publishes the Factbook. This is an up-to-date business planning tool for decision makers in the pharmaceutical industry, including R&D, corporate finance, business strategy, marketing planning and corporate communications professionals. Since 1994, CMR International has worked with leading global pharmaceutical and biotechnology companies to assess R&D productivity and provide insights which help organizations to improve the planning and effectiveness of R&D.

The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 percent of the industry's global R&D expenditure. The CMR International 2009 Pharmaceutical R&D Factbook is available as single-user or enterprise-wide editions, in either electronic or hard copy format.

For further information, please go to:

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
2. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
5. Thomson Scientific Begins Expansion of Web of Science
6. Thomson Reuters Launches New Biomarkers Solution
7. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
8. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
9. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
10. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
11. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
Post Your Comments:
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , ... Annual Healthcare Conference in New York City ... (1:30 p.m. GMT). --> SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> Shire ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):